From eMaxHealth.com, posted 08-20-2007
http://www.emaxhealth.com/33/15107.html

Study Combines HIFU, Chemotherapy For Localized Prostate Cancer

EDAP TMS is currently conducting clinical investigations in France under an
approved clinical trial combining the company's Ablatherm-HIFU device with
chemotherapy using docetaxel.

The study is a primary treatment therapy program for men suffering from
clinically localized but aggressive high risk prostate cancer typically
classified as stage T2c. The study began in late 2006 and will enroll a
total of 30 men, of which more than 10 have already been treated.

"Combination therapy is well documented as a treatment protocol for men
suffering more aggressive prostate cancers," said Dr. Albert Gelet, Edouard
Herriot Hospital, Lyon. "Ablatherm-HIFU is a proven effective treatment for
localized prostate cancer already with strong clinical support. This study
aims to evaluate its use under an additional dedicated protocol for men in
the T2c cancer stage where the tumors are known to be more aggressive,
creating a higher risk of relapse if the patient is treated with only a
localized therapy. It was demonstrated in pre-clinical studies that HIFU
improves chemotherapy drug efficacy in the area around burned tissues."

Under the approved protocol by French Ethical Committee, patients are
administered a dose of docetaxel 30 minutes prior to a standard primary
indication HIFU session lasting an average of two hours. The Ablatherm-HIFU
ablates the prostate tissue according to conventional procedures and
protocols. All treatments are administered at Edouard Herriot Hospital in
Lyon, France.